Novartis AG’s blockbuster heart failure drug Entresto is among a handful of products now undergoing Medicare price negotiation that are likely to test the Centers for Medicare and Medicaid Services’ policy around what happens if generic or biosimilar competition enters the market before the negotiated price is implemented in 2026.
Key Takeaways
-
Nearly half the drugs currently undergoing the Medicare price negotiation process, including Entresto, will face competition from generics or biosimilars before the negotiated prices go into effect in 2026, heightening interest in the government’s approach to dealing with such situations.
The issue came up during Novartis’ fourth quarter earnings call on 31 January. Asked what will happen to Entresto's negotiated...







